Skip to content
Clinical Trials – home
Not yet recruiting

Study of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension

InvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The condition being studied is Pulmonary arterial hypertension, a disease in which high pressure builds up in the arteries that carry blood from the heart to the lungs, making it hard to breathe and to exercise. The treatment being tested combines three medicines: a drug that blocks a protein called endothelin (known as an endothelin receptor antagonist), a pill that helps relax blood vessels by inhibiting an enzyme (a phosphodiesterase-5 inhibitor), and a newer agent called sotatercept given as a subcutaneous injection, which means it is administered under the skin.

The purpose of the study is to see if this three‑drug approach can be given safely and followed for 24 weeks in people who have just been diagnosed with the disease. Participants will receive the injection of the study drug and take the oral medicines each day, with regular clinic visits to monitor how they feel, to check blood work, to measure the distance walked in six minutes (6MWD), and to have an ultrasound of the heart (echocardiography). Doctors will also look at numbers that reflect how hard the heart is working, such as pulmonary vascular resistance, mean pulmonary artery pressure, cardiac index, and a blood marker called NT‑proBNP, all to understand the effect of the treatment over the study period.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    After you join the study, you will undergo a series of initial examinations to confirm your diagnosis of pulmonary arterial hypertension (PAH).

    These examinations include a physical check, blood tests, an echocardiogram (an ultrasound of the heart), and a right‑heart catheterization that measures the pressure in your lungs and the resistance of your pulmonary vessels.

    The results of these tests establish the starting values for later comparisons and ensure that you meet the study’s eligibility criteria.

  2. Step 2

    Start of Triple Therapy

    Once the baseline assessments are complete, you will begin the study medication regimen, which combines three types of drugs:

    Endothelin receptor antagonist (ERA) – an oral tablet taken once daily that helps relax blood vessels in the lungs.

    Phosphodiesterase‑5 inhibitor (PDE5i) – an oral tablet taken once daily that also helps widen the lung arteries.

    Sotatercept – a solution for subcutaneous injection given at a dose of 0.7 mg per kilogram of your body weight. The injection is administered by a qualified professional.

    The first injection of sotatercept is given shortly after you start the oral medicines.

  3. Step 3

    Ongoing Medication Administration

    You will continue to take the ERA and the PDE5i tablets every day for the entire 24‑week study period.

    Sotatercept will be injected subcutaneously at the same dose (0.7 mg/kg) on a regular schedule, typically once every four weeks, as directed by the study team.

    Each injection is performed in a clinic setting to ensure correct dosing and technique.

  4. Step 4

    Regular Follow‑Up Visits

    You will return to the clinic for follow‑up visits at weeks 4, 8, 12, 16, 20, and 24.

    During each visit, the study staff will check your safety and how well you are tolerating the medicines. This includes blood tests, assessment of any side effects, and measurement of vital signs.

    You will also undergo functional assessments such as the six‑minute walk test (6MWD), which records how far you can walk in six minutes, and a repeat echocardiogram to monitor heart function.

    The dose of sotatercept will be administered at the visits scheduled for weeks 4, 8, 12, 16, 20, and 24.

  5. Step 5

    Final Evaluation at Week 24

    At the end of the 24‑week period, you will have a comprehensive evaluation that repeats the baseline measurements.

    Key measurements include mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR) expressed in Wood units (WU), cardiac index, NT‑proBNP blood level, and WHO functional class (WHO‑FC) which describes symptom severity.

    The study will also record any serious adverse events, such as hospitalization for worsening PAH, and assess whether you have reached low‑risk criteria defined by international guidelines.

    These results determine the overall safety, feasibility, and effectiveness of the triple‑therapy approach.

Who can join the trial?

10 criteria

  • Be between 18 and 70 years old.
  • Have a new diagnosis of pulmonary arterial hypertension (PAH) made within the past 12 weeks, either idiopathic/heritable/drug‑induced PAH or PAH linked to a heart defect that was corrected at least 12 months ago, no matter what WHO functional class (a measure of symptom severity) you have.
  • If you are already taking an ERA (a drug that blocks a molecule called endothelin) or a PDE5i (a drug that helps relax blood vessels), you must have started that medication after a right heart catheterization (RHC) that was performed no more than six weeks ago.
  • At the time of diagnosis you must have:
    • Pulmonary vascular resistance (PVR) greater than 5 Wood units (a measure of how hard it is for blood to flow through the lungs),
    • Mean pulmonary arterial pressure (mPAP) of 35 mmHg or higher (the average pressure in the lung arteries), and
    • Pulmonary artery wedge pressure (PAWP) or left ventricular end‑diastolic pressure (LVEDP) of 15 mmHg or less (measures that help rule out other heart problems).
    • Sign a written informed consent form agreeing to take part in the study.
    • If you are a woman who could become pregnant, you must have a negative result on a highly sensitive pregnancy test and agree to have a pregnancy test each month during the study and until 112 days after the last dose of the study drug Sotatercept.
    • If you are a woman who could become pregnant, you must use a highly effective method of contraception (such as hormonal birth control, an intrauterine device, tubal ligation, a vasectomised partner, or agreed sexual abstinence) that you have been using for at least eight weeks before joining the study and continue it during treatment and until 112 days after the last dose of Sotatercept.
    • If you are a sexually active man with a partner who could become pregnant, you must agree to use a condom and your partner must follow the same contraception requirements described above.

Who cannot join the trial?

17 criteria

  • Having any other type of pulmonary hypertension or pulmonary arterial hypertension that is not covered by this study.
  • Having a kidney function measured as eGFR lower than 30 ml/min/1.73 m² at the screening visit (eGFR is a test that shows how well the kidneys are working).
  • Being pregnant or breastfeeding.
  • Being allergic (hypersensitive) to the study medicines or any of their ingredients.
  • Having taken other PAH medications for more than 6 weeks before the screening.
  • Being diagnosed with PAH more than 3 months before the screening.
  • Having significant lung disease, shown by any of the following:
    • a total lung capacity (TLC) less than 70% of normal (TLC measures the total amount of air the lungs can hold),
    • a FEV1/FVC ratio less than 60% (a test of airflow obstruction),
    • or a DLCO less than 45% (DLCO measures how well oxygen moves from the lungs into the blood).
    • Having signs of left‑side heart failure, such as:
      • a left ventricular ejection fraction (LVEF) under 50% (how much blood the left heart pumps out with each beat),
      • a left atrial volume index (LAVI) over 34 ml/m² (size of the left atrium),
      • an E/é measurement of 15 or higher (a Doppler ultrasound measure of heart pressure),
      • or permanent atrial fibrillation (an irregular heart rhythm).
      • Having a hemoglobin level (the protein that carries oxygen in the blood) lower than 8 g/dL, higher than 17 g/dL for women, or higher than 19 g/dL for men.
      • Having a platelet (or thrombocyte) count lower than 80,000 per microliter.
      • Being judged by the doctor to have a high risk of bleeding.
      • Currently receiving prostacyclin analogues or prostacyclin receptor agonists (specific medicines used for PAH).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Sotatercept

    is a medication given by injection under the skin. It works by helping the body repair and remodel the blood vessels in the lungs, which can become narrowed in pulmonary arterial hypertension. In this study, patients receive sotatercept as part of a three‑drug combination to see if it can lower the pressure in the lung arteries and improve heart function.

  • Endothelin receptor antagonist

    is a type of drug that blocks the action of endothelin, a substance that makes blood vessels tighten. By blocking this effect, the medication helps the blood vessels in the lungs relax and widen, allowing blood to flow more easily. In the trial, it is used together with the other two drugs to reduce the strain on the heart caused by high pressure in the lungs.

  • Phosphodiesterase‑5 inhibitor

    is a medication that increases the levels of a natural chemical that relaxes the muscles in the walls of blood vessels. This helps the vessels in the lungs open up, lowering the pressure that the heart has to pump against. In the study, it is combined with the endothelin receptor antagonist and sotatercept to provide a comprehensive approach to treating newly diagnosed pulmonary arterial hypertension.

What is already known about the treatment

sotatercept - It is given as a solution for injection that is administered under the skin (subcutaneous injection). Sotatercept is an approved drug for pulmonary arterial hypertension and is also being studied in clinical trials for this condition. It works by binding to certain proteins called activins, which helps reduce abnormal growth of blood‑vessel cells in the lungs. It is classified as an activin‑type II receptor ligand trap, a biologic therapy that modifies growth‑factor signaling.

Investigated diseases

Pulmonary arterial hypertension - Pulmonary arterial hypertension is a condition in which the blood vessels that carry blood from the heart to the lungs become narrowed or stiff. This narrowing raises the pressure that the right side of the heart must generate to push blood through the lungs. Over time, the increased workload can cause the right side of the heart to enlarge and function less efficiently. Symptoms often begin with shortness of breath during activity, fatigue, and sometimes swelling in the ankles or legs. The disease typically progresses slowly, with pressure in the lung arteries gradually increasing if it is not controlled.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IITrial ID2025-522266-67-00Protocol codeKKS-322Estimated enrolment2 patientsSponsorPhilipps-Universitaet Marburg

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.